Description: c-erbB-2 (HER-2/neu) is a 185 kDa receptor tyrosine kinase belonging to the epidermal growth factor receptor family, which also includes EGFR (HER-1), c-erbB-3 (HER-3), and c-erbB-4 (HER-4). Amplification of the HER-2 gene with overexpression of the protein occurs in 20-30% of breast cancers, and tumor progression in mammary cancer is associated with elevated levels of tyrosine-phosphorylated neu and erbB-3. Tyr is the phosphorylation site that is most tightly linked to oncogenic transformation and coupling to the ras/MAP kinase signaling pathway. Cases of invasive breast carcinoma with the phosphorylated receptor have displayed aggressive clinicopathological features and adverse prognoses. Activation of HER-2 is frequent in ductal carcinoma in situ suggesting that HER-2 signaling plays a critical role in the early stages of breast tumorigenesis.
Primary Antibody
|
Name: c-erbB-2/HER-2/neu (phospho-specific) Ab-18 Antibody |
|
Clone: PN2A, Mouse |
|
Supplier: Lab Vision |
|
Catalog Number: MS-1072-P |
|
Dilution: 1:20 |
|
Incubation Time/Temp: 60 minutes/room temperature |
| Device: Steamer |
| Buffer/pH value: Tris-EDTA/pH 9.0 |
| Heat/Cool Temperature: 95-100 ºC/room temperature |
| Heat/Cool Time: 20 minutes/20 minutes |
| Standard Method: ABC Method or LSAB Method |
| Enhanced Method: Polymeric Methods |
| Reagent: DAB |
| Incubation Time/Temperature: 1-3 minutes/room temperature |
| Reagent: Gill's Hematoxylin or Mayer's Hematoxylin |
| Staining Time: 30 seconds |
| Staining Pattern: Membrane |
| Images: Search image |
| Tissue Type: Breast |
| Fixation: Formalin fixed paraffin sections |
| Positive Control: EGF-treated SKBR3 cells. About 5% of breast carcinomas are positive for phospho-c-erbB-2/HER-2/neu oncoprotein. |
| Negative Control: Omit primary antibody, isotype control or absorption control |
| Blocking: 2-5% normal serum to reduce unspecific background staining; 0.5-3% H2O2 to block endogenous peroxidase activity; avidin/biotin to block endogenous biotin activity if necessary |
References: